Chronic Hepatitis C Clinical Trial
Official title:
A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 and to Evaluate the Antiviral Activity in Hepatitis C Virus Infected Patients
A Phase 1, First-in-Human, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 in Healthy Volunteers and to Evaluate the Antiviral Activity of MB-110 in Hepatitis C Virus Infected Subjects
The present study is divided into 2 parts. Part A is a randomized, double blind, placebo
controlled, sequential ascending single and multiple oral doses design to evaluate the
safety, tolerability, PK, and food effect of MB-110 in healthy volunteers.Part A will
recruit 2 groups (Groups 1 and 2) of 8 healthy volunteers in each group. Within each group,
8 subjects will be randomized 6:2 to receive MB-110 versus placebo.Subjects in Group 1 will
receive either 50 mg of MB-110 or placebo under fasted conditions during the first visit
(Cohort 1); and either 50 mg of MB-110 or placebo under fed conditions during the second
visit (Cohort 3) where food effect will be evaluated. Subjects in Group 2 will receive
either 100 mg of MB-110 or placebo under fasted condition during the first visit (Cohort 2);
or 200 mg of MB-110 or placebo under fasted condition during the second visit (Cohort 4). In
Cohort 5, 8 subjects will be selected from Group 1, Group 2, or new recruitment if the
washout time is insufficient from the previous cohort. Subjects in Cohort 5 will be
randomized 6:2 to receive MB-110 at dose of 200 mg or placebo once daily for 5 consecutive
days.
Part B is a randomized, double-blind, placebo-controlled, multiple ascending oral dose
design to evaluate the safety, tolerability, PK, and antiviral activity of MB-110 in
subjects infected with Hepatitis C virus genotype 1b, 2a, and 3a.Part B will recruit 3
cohorts (Cohorts 6, 7, and 8) of treatment-naïve HCV infected subjects in each cohort. In
Cohort 6, 12 subjects infected with Hepatitis C virus genotype 1b will be randomized 5:5:2
to receive two dose levels of MB-110 or placebo once daily for 3 consecutive days. In Cohort
7, 6 subjects infected with Hepatitis C virus genotype 2a will be randomized 5:1 to receive
MB-110 or placebo once daily for 3 consecutive days. In Cohort 8, 6 subjects infected with
Hepatitis C virus genotype 3a will be randomized 5:1 to receive MB-110 or placebo once daily
for 3 consecutive days.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01937975 -
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
|
Phase 1 | |
| Completed |
NCT03673696 -
The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT02250001 -
Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
|
N/A | |
| Completed |
NCT03088917 -
'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
|
||
| Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
| Not yet recruiting |
NCT02865369 -
Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment
|
N/A | |
| Recruiting |
NCT02638233 -
Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy
|
Phase 4 | |
| Not yet recruiting |
NCT02511496 -
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
|
N/A | |
| Completed |
NCT02788682 -
Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy
|
N/A | |
| Not yet recruiting |
NCT01949168 -
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
|
Phase 2 | |
| Completed |
NCT01439776 -
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
|
Phase 4 | |
| Recruiting |
NCT01360879 -
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
|
N/A | |
| Recruiting |
NCT01360892 -
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
|
N/A | |
| Terminated |
NCT00962936 -
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
|
Phase 1/Phase 2 | |
| Completed |
NCT00968357 -
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
|
Phase 2 | |
| Recruiting |
NCT01178749 -
Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments
|
N/A | |
| Recruiting |
NCT00575627 -
Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels
|
Phase 4 | |
| Completed |
NCT00537407 -
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
|
Phase 2 | |
| Recruiting |
NCT00370617 -
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance
|
Phase 4 | |
| Completed |
NCT01684787 -
Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients
|
Phase 4 |